GLP1R and type 2 diabetes mellitus: We applied the methods to an illustrative example in type 2 diabetes assessing the impact of treatments within two classes of glucose-lowering medications; sodium-glucose co-transporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) [16].